Phase II study of gemcitabine in advanced colorectal adenocarcinoma (Q67993427)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

title

Phase II study of gemcitabine in advanced colorectal adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

colorectal adenocarcinoma

20 September 2019

main subject

1 reference

D. F. Moore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1487408

1 October 2022

R. Pazdur

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1487408

1 October 2022

K. Daugherty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1487408

1 October 2022

P. Tarassoff

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1487408

1 October 2022

J. L. Abbruzzese

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1487408

1 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1487408

1 October 2022

publication date

1 November 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

20 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

page(s)

323-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1487408%20AND%20SRC:MED&resulttype=core&format=json

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

20 September 2019

cites work

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas

1 reference

12 December 2020

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer

1 reference

12 December 2020

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

1 reference

12 December 2020

Improvements in fluorouracil chemotherapy?

1 reference

12 December 2020

Treatment of advanced colorectal cancer

1 reference

12 December 2020

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

1 reference

12 December 2020